AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2024
Jun 25, 2024
30604_dirs_2024-06-25_381c835e-4abb-4ac2-b7a0-4eab560ebd25.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-06-21
Reporting Person: MCCORMICK FRANK (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-21 | Stock Option (Right to Buy) | $27.36 | A | 26014 | Acquired | 2034-06-20 | Common Stock (26014) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 120086 | Direct |
| Common Stock | 979979 | Indirect |
Footnotes
F1: Excludes 352,290 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on April 16, 2024.
F2: Includes 352,290 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on April 16, 2024.
F3: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer.